Selective Tumor Localization and Improved Therapeutic Index of Anthracyclines Encapsulated in Long-Circulating Liposomes

Cancer Research

Volumn 52, Issue 4, 1992, Pages 891-896

  Gabizon, Alberto A ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIRUBICIN; LIPOSOME; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL;

ADOLESCENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES FLUID; ASCITES TUMOR; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TISSUE LEVEL; DRUG TOXICITY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PHARMACEUTICS; PLASMA CLEARANCE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR LOCALIZATION;

ANIMAL; DOXORUBICIN; DRUG CARRIERS; EPIRUBICIN; FEMALE; LIPOSOMES; LIVER; LYMPHOMA; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MUSCLES; MYOCARDIUM; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; PHOSPHATIDYLINOSITOLS; SUPPORT, NON-U.S. GOV'T; TISSUE DISTRIBUTION;

EID: 0026603586     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Poznansky, M. J., and Juliano, R. L. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol. Rev., 36: 277-336, 1984.
2. Senior, J. H. Fate and behavior of liposomes in vivo: a review of controlling factors. CRC Crit. Rev. Ther. Drug Carrier Syst., 3: 123-193, 1987.
3. Hwang, K. J. Liposome pharmacokinetics. In: M. J. Ostro (ed.). Liposomes: From Biophysics to Therapeutics, pp. 109-156. New York: Marcel Dekker, Inc., 1987.
4. Allen, T. M., Hansen, C., and Rutledge, J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial system and other tissues. Biochim. Biophys. Acta, 981: 27-35, 1989.
5. Gabizon A., and Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA, 5:6949-6953, 1988.
6. Allen T. M. Stealtha.,c liposomes: avoiding reticuloendothelial uptake. In: G. Lopez-Berestein and I. J. Fidler (eds.). Liposomes in the Therapy of Infec tious Diseases and Cancer, pp. 405-415. New York: Alan R. Liss, Inc., 1989.
7. Gabizon, A., Price, D. C., Huberty, J., Bresalier, R. S., and Papahadjopoulos, D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Can cer Res., SO:6371-6378, 1990.
8. Gabizon, A., Shiota, R., and Papahadjopoulos, D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Nat!. Cancer Inst., 81: 1484-1488, 1989.
9. Lichtenberg, D., and Barenholz, Y. Liposomes: preparation, characterization, and preservation. Methods Biochem. Anal., 33: 337-462, 1988.
10. Storm, G., Van Bloois, L., Brouwer, M., and Crommelin, D. J. The inter action of cytostatic drugs with adsorbents in aqueous media: the potential implications for liposome preparation. Biochim. Biophys. Acta. 515: 343-351, 1985.
11. Bartlett, G. R. Phosphorus assay in column chromatography. J. Biol. Chem., 254:466-468,1959.
12. Gabizon, A., Goren, D., Fuks, L., Meshorer, A., and Barenholz, Y. Superior therapeutic efficacy of liposome-associated Adriamycin in a murine metastatic tumor model. Br. J. Cancer. 51: 681-689, 1985.
13. Druckmann, S., Gabizon, A., and Barenholz, Y. Separation of liposomeassociated doxorubicin from protein-bound and free doxorubicin: implica tions for pharmacokinetic studies. Biochim. Biophys. Acta, 980: 381-384, 1989.
14. Takanashi, S., and Bachur, N. R. Adriamycin metabolism in man: evidence from urinary metabolites. Drug Metab. Dispos., 4: 79-87, 1976.
15. Gabizon, A., Meshorer, A., and Barenholz, Y. Comparative study of the toxicities of free and liposome-associated doxorubicin after intravenous in jection in mice. J. Natl. Cancer Inst., 77: 459-469, 1986.
16. Kirkwood, B. R. Essentials of Medical Statistics. Oxford: Blackwell, 1988.
17. Barter, P. J., and Lally, J. I. The activity of an esterified cholesterol transfer ring factor in human and rat serum. Biochim. Biophys. Acta, 531: 233-236, 1978.
18. Szoka, F. C. Liposomal drug delivery: current status and future prospects. In: J. Wilschut and D. Hoekstra (eds.). Membrane Fusion, pp. 845-890. New York: Marcel Dekker, Inc., 1991.
19. Ogihara. I., Kojima, S., and Jay, M. Tumor uptake of “Ga-carrying lipo somes. Eur. J. Nuc. Med., 11: 405-411, 1986.
20. Gabizon, A., Peretz, T., Sulkes, A., Amselem, S., Druckmann, S., Ben-Yosef, R., Ben-Baruch, N., Catane, R., Biran, S., and Barenholz, Y. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur. J. Cancer Clin. Oncol., 25:1795-1803, 1989.
21. Rahman, A., Treat, J., Roh. J. K., Ptokul, L., Alvord, W., Forst, D., and Wolley, P. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J. Clin. Oncol., 8: 1093-1100, 1990.
22. Cowens, J. W., Creaven, P. J., Brenner. D. E., Ginsberg. R., Petrelli, N., Hben,R., Karakusis, C., Douglass, H., Mayer. L., Bally, M., Cullis, P., Goolsby, H., and Solomon, J. Phase I study of doxorubicin encapsulated in liposomes. Proc. Am. Soc. Clin. Oncol., 9: 87, 1990.
23. Mayhew, E. G., Goldrosen, M. H., Vaage, J., and Rustum, Y. M. Effects of liposome-entrapped doxorubicin on liver mtastasesof mouse colon carci nomas 26 and 38. J. Natl. Cancer Inst., 78: 707-713, 1987.
24. Gabizon, A., Goren, D., and Barenholz. Y. Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models. Isr. J. Med. Sci., 24:512-517, 1988.
25. Forssen, E. A. Chemotherapy with anthracycline liposomes. In: G. Gregoriadis (d.). Liposomes as Drug Carriers, pp. 355-364. Chichester: John Wiley & Sons, Ltd., 1988.
26. Papahadjopoulos, D., Allen, T., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K-D., Woodle, M. C., Lasic, D. D., Redemann, C., and Martin, F. J. Sterically stabilized liposomes: improvements in pharmacokinetics and anti-tumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA, KK: 11460-11464,1991.
27. Blume, G., and Cevc, G. Liposomes for sustained drug release in vivo. Biochim. Biophys. Acta, 1029:91-97, 1990.
28. Klibanov, A. L., Maruyama, K., Torchilin, V. P., and Huang, L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett., 26:235-237, 1990.
29. Jain, R. K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev., 9: 253-266, 1990.
30. Weinstein, J. N., Magin, R. L., Yatvin, M. B., and Zaharko, D. S. Liposome and local hyperthermia: selective delivery of methotrexate to heated tumors. Science (Washington DC), 204: 188-191, 1979.
31. Chu, C. J., Dijkstra, J., Lai, M. Z., Hong, K., and Szoka, F. C. Efficiency of cytoplasmic delivery by pH-sensitive liposomes to cells in culture. Pharm. Res. (NY), 7: 824-834, 1990.